Kura Oncology Inc [KURA] stock prices are down -1.93% to $8.65 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KURA shares have gain 9.36% over the last week, with a monthly amount glided 5.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on February 06, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $27. On October 14, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $19 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $26 on December 22, 2023. BofA Securities initiated its recommendation with a Buy and recommended $31 as its price target on August 11, 2023. Scotiabank started tracking with a Sector Perform rating for this stock on July 27, 2023, and assigned it a price target of $10.50. In a note dated May 17, 2023, BTIG Research initiated an Buy rating and provided a target price of $31 on this stock.
The stock price of Kura Oncology Inc [KURA] has been fluctuating between $6.98 and $24.17 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $8.65 at the most recent close of the market. An investor can expect a potential return of 119.65% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -171.26%, Pretax Profit Margin comes in at -155.55%, and Net Profit Margin reading is -155.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.44 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.42 points at the first support level, and at 8.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.93, and for the 2nd resistance point, it is at 9.21.
Ratios To Look Out For
It’s worth pointing out that Kura Oncology Inc [NASDAQ:KURA]’s Current Ratio is 11.47. As well, the Quick Ratio is 11.47, while the Cash Ratio is 1.23.
Transactions by insiders
Recent insider trading involved DOYLE THOMAS JAMES, SVP, Finance & Accounting, that happened on Jan 28 ’25 when 4949.0 shares were sold. Chief Medical Officer, Leoni Mollie completed a deal on Jan 28 ’25 to sell 4963.0 shares. Meanwhile, Chief Legal Officer Bair Teresa Brophy sold 7281.0 shares on Jan 28 ’25.
